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ent with dyspnea, recurrent infections, intractable cough, or
retained secretions. Airway stabilization may be accom-
plished with silicone stenting, which provides patients
with symptom relief in a minimally invasive manner. How-
ever, this technique is not without complications, which
mostly occur by 3 weeks. Surgical stabilization is the defin-
itive treatment of TBM.1 We review the evaluation of TBM
and options for treatment.CLINICAL EVALUATION
To be considered for interventions to stabilize the airway,
patients must have documented severe TBM. Severe and
diffuse TBM is manifest by complete or near-complete col-
lapse of the trachea and bilateral bronchi. This is best diag-
nosed via functional bronchoscopy and dynamic computed
tomography scanning. Functional bronchoscopy is per-
formed under light sedation to allow for the patient to follow
commands. The airway should be evaluated initially in the
proximal trachea, and the patient is coached to perform
forced inspiratory and expiratory maneuvers. These maneu-
vers are then repeated in the distal trachea and the proximal
bilateral mainstem bronchi. Bronchoscopic estimates of the
degrees of collapsibility are recorded at each station.
In addition to bronchoscopy, dynamic computed tomogra-
phy should be performed according to a central airway proto-
col, which includes end-inspiratory and dynamic expiratory
imaging.2 Scout images are initially taken to determine the
area of coverage, including the trachea and central bronchi.
The helical scanning is performed in a craniocaudal direction
during both end-expiratory and dynamic-expiratory phases.
The percentage of luminal collapse is determined by subtract-
ing the estimated dynamic expiratory cross-sectional area
from the end-inspiratory cross-sectional area, divided by
the end-inspiratory cross-sectional area. Although the defini-
tion of malacia is greater than 50% cross-sectional luminal
collapse, symptomatic TBM, which will require treatment,
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S58 The Journal of Thoracic and Cardiovascular SurgBefore consideration for surgical repair, patients should
undergo a thorough screening of symptoms and functional
status. This evaluation typically involves pulmonary func-
tion tests, 6-minute walk test (6MWT), and determination
of Karnofsky performance status, American Thoracic Soci-
ety (ATS) dyspnea score, and respiratory-affected quality of
life based on the St George Respiratory Questionnaire
(SGRQ). Significant derangement of the patient’s func-
tional status and quality of life is necessary before consider-
ing potential intervention.TREATMENT OPTIONS
Endoscopic stabilization of the central airways is accom-
plished by placement of a Y-shaped silicone stent. Tubular
silicone stents have been found to have high rates of migra-
tion. TheY-stent is placed via rigid bronchoscopy under gen-
eral anesthesia. Patients are then evaluated 2 weeks after this
procedure for improvement of symptoms. In our initial series
of 58 patients treated with silicone stents, we demonstrated
that stenting improved the SGRQ score, Karnofsky perfor-
mance status, ATS dyspnea score, and baseline dyspnea in-
dex/transitional dyspnea index.3 These patients had an
average age of 69 years, and nearly all (n¼ 57) patients pre-
sented with dyspnea as the sole symptom or along with
cough and recurrent infection. Complications from stent
placement typically occurred with longer dwell time, and in-
cluded stent obstruction from mucus plugging (n ¼ 21), in-
fection (n ¼ 14), stent migration (n ¼ 10), severe cough
(n¼ 3), subglottic edema (n¼ 3), and stent breakage (n¼ 1).
In another series of 94 patients with TBM and chronic ob-
structive pulmonary disease, 49% were able to achieve
symptomatic relief after stent placement.4 When these pa-
tients were stratified by Global Initiative for Chronic Ob-
structive Lung Disease stage, all patients except for those
in stage 1 demonstrated an increase in forced expiratory
volume in 1 second (FEV1). This study also determined
that operative intervention had the greatest advantage in
the group of patients undergoing surgical intervention.
Because of the complications associated with chronic
stent placement, definitive treatment with surgical stabiliza-
tion is considered for those patients with marked improve-
ment after a stent trial. If patients report minimal
improvement of dyspnea with a stent, it is less likely that
surgery will yield a positive outcome. Surgical intervention
involves the stabilization of the posterior membranous wall
of the intrathoracic trachea up to the thoracic inlet and both
mainstem bronchi and bronchus intermedius. In contradis-
tinction to stent stabilization, the repair is completely extra-
luminal. The stabilization is achieved by suturingery c September 2012
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way for it to act as a splint.
Multiple rows of sutures typically are used to anchor the
mesh to the airway, and case durations average approxi-
mately 6 hours. Patients generally spend the first 48 to 72
hours in the intensive care unit, and the average length of
stay is 8 days. Despite the arduous nature of the operation
and recuperation, approximately 75% of these patients
can be discharged, without the need for a stay at a rehabili-
tation facility.1
Complications were observed in 38% of patients in our
series, the most common being the development of new
postoperative respiratory infection, which occurred in
22%.1 Other complications include prolonged mechanical
ventilation or reintubation, tracheostomy tube placement,
atrial fibrillation, and hemothorax. The mortality rate is
3%, despite the multiple comorbidities and pulmonary in-
sufficiency that many of these patients have.
When the functional outcomes of these patients were
evaluated, statistically significant improvements were seen
in Karnofsky performance status (62  12 vs 76  14,
P<.001), ATS dyspnea score (3.06  0.6 vs 1.65  1.01,
P< .001), SGRQ (74  13 vs 46  21, P< .001), and
6MWT (987  502 vs 1187  347 feet, P<.005). We did
not detect an improvement in FEV1, although in a series
of 14 patients who underwent tracheobronchoplasty,Wright
and colleagues5 demonstrated a statistically significant in-
crease in FEV1 from 51.2% to 73.5% (P ¼ .0009). Forced
vital capacity increased from 68% to 79.8% (P¼ .01), and
predicted peak expiratory flow rate increased from 49% to
70% (P<.0001). Long-term quality of life assessment in
that study revealed that 7 patients reported greater than
75% subjective improvement in symptoms.
Stabilization of the central airways using endoscopy with
yttrium aluminum perovskite laser treatment and animal
models demonstrating cure of tracheal collapse withThe Journal of Thoracic and Caorally administered stanozolol are potentially interesting al-
ternative therapies.6,7 These interventions will need further
study to define their applicability.
CONCLUSIONS
Appropriate treatment of severe, diffuse TBM involves
a coordinated effort among pulmonologists, radiologists,
and surgeons. Anatomic definition of TBM with dynamic
computed tomography and functional bronchoscopy, as
well as evaluation of the severity of its impact via subjective
assessment tools and 6MWT, helps identify patients who
may benefit from treatment. Silicone stents are used as a trial
to see whether more definitive surgical stabilization will
yield benefit. Tracheobronchoplasty is an effective and
safe intervention for TBM. Further study should be directed
to prospective analysis of the benefit of treatment and
the development of more reliable assays of objective
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